Managed Care Approaches to Equitable Access to Recombinant Adeno-Associated Virus (rAAV) Gene Therapy
Pricing: Free for Members and Non-Members
This activity is supported by an educational grant from Pfizer, Inc.
Course Description
Gene therapies, such as recombinant adeno-associated virus (rAAV) vector technology, have arrived. Understanding the current and future impact is essential for payers, particularly with growing rAAV gene therapy innovation for rare genetic diseases and the complexities of access, cost, and durability of these therapies. This session will review the existing and pipeline rAAV gene therapy landscape, insights into payer management strategies, and the associated difficulties and solutions related to access for a diverse population.
Target Audience
Pharmacists who practice in managed care settings.
Learning Objectives
At the completion of this activity, participants should be able to:
- Define the evolution of recombinant adeno-associated virus (rAAV) gene therapy.
- Discuss new and emerging advances in the use of rAAV gene therapy based on efficacy, safety, durability, policy, and clinical utilization.
- Discuss health disparities related to access to rAAV gene therapy for a diverse population.
- Identify managed care strategies that address health disparities and equitable access to rAAV gene therapy for eligible patients.
Faculty
Michelle Booth, PharmD (she/her/hers)
Sr. Director, Specialty Clinical Solutions
Magellan Rx Management
Middletown, RI
Andy Killpack, PharmD
Director, Specialty Clinical Solutions
MagellanRx
South Jordan, UT
Moderator
Kimberly Glenn, PhD, MPH
VP HEOR Research Consulting
Optum
Eden Prairie, Minnesota
Financial Relationship Disclosures
Faculty/Reviewer/Planner | Reported Relevant Financial Relationships |
Michelle Booth Faculty | Disclosed no relevant financial relationships. |
Andy Killpack Faculty | Disclosed no relevant financial relationships. |
Alan Chuang | Disclosed no relevant financial relationships. |
Jennifer Evans Planner | Disclosed no relevant financial relationships. |
- AMCP Staff have disclosed no relevant financial relationships.
- If applicable, relevant financial relationships have been mitigated and documented.
- Content has undergone a peer review to ensure content validity.
Accreditation:
The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
ACPE UAN:0233-0000-23-007-H01-P • Activity Type: Knowledge-Based
Contact Hours: 1.25
Release Date: March 23, 2023 • Expiration Date: December 31, 2024
Activity Fee: Free for Members and Non-Members
Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live activity presented at AMCP 2023. CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your NABP account.
To receive credit for an online activity you must:
- Review the full content of the activity.
- Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
- Complete a specific activity evaluation.
Available Credit
- 1.25 ACPEThe Academy of Managed Care Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
- 1.25 Certificate of Completion